Madrigal Pharmaceuticals stock analysis: 71% revenue growth meets a rich 24x price-to-book near two-year highs. Model signal: Hold.
@2026 – All Right Reserved.
-
-
SoftwareUS Stocks
CoreWeave Is Burning $9 Billion a Year to Chase AI Demand – Can the Balance Sheet Keep Up?
CoreWeave stock analysis: 112% revenue growth collides with a -$9.1B free cash flow and 10x leverage. Model signal: Sell.
-
BiotechnologyUS Stocks
IDEAYA Biosciences: Trading Near a Two-Year High While the Model Flags a Sell
IDEAYA Biosciences, Inc. stock analysis: shares sit near a two-year high while a -36.4% gross margin and 25/100 quality score drive a Sell signal.
-
Insmed Incorporated stock analysis: revenue up 296.1% with a 90/100 growth score, offset by a -76.9% net margin and a Hold signal from our model.
-
IREN Limited stock analysis: a 68.9% gross margin offset by $4.2B of cash burn, revenue down 26.7%, and a Sell signal from our scoring model.
-
Hut 8 Corp. stock analysis: HUT has run roughly 10x off its two-year low, but a 22/100 Quality score and heavy cash burn make it a model Sell.
-
Cerebras Systems Inc. stock analysis: CBRS grew revenue 74.3% to $681M, but deep losses and missing valuation data leave the model with no signal.